A practitioner's toolkit for managing the menopause. The North American Menopause Society. Clinical Care Recommendations. Chapter Medical eligibility criteria for contraceptive use. Geneva: World Health Organization Press; A scheme of combined oral contraceptives for women more than 40 years old. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study.
Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. Long term hormone therapy for perimenopausal and postmenopausal women.
Cochrane Database Syst Rev. Huang KE. Menopause perspectives and treatment of Asian women. Semin Reprod Med. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10, British women aged Mishra GD, Kuh D.
Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. Int J Fertil Womens Med. Epidemiologic survey of menopausal and vasomotor symptoms in Korean women. J Korean Soc Menopause.
Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Low-dosage esterified estrogens opposed by progestin at 6-month intervals.
Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. The climacteric symptoms and quality of life in climacteric women according to hormone replacement therapy. Korean J Women Health Nurs. Influences of hormone therapy to tissue mineral concentration and quality of life in menopausal women.
Assessment about quality of life in menopausal women with hormone replacement therapy. Korean J Obstet Gynecol. Does estrogen enhance the antidepressant effects of fluoxetine? J Affect Disord. Update on management of genitourinary syndrome of menopause: a practical guide. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI.
Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Local oestrogen for vaginal atrophy in postmenopausal women. Management of symptomatic vulvovaginal atrophy: position statement of The North American Menopause Society. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
Efficacy of intravaginal dehydroepiandrosterone DHEA on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. An assessment of the safety and efficacy of a fractional CO 2 laser system for the treatment of vulvovaginal atrophy. Food and Drug Administration. FDA Warns against use of energy-based devices to perform vaginal 'rejuvenation' or vaginal cosmetic procedures: FDA safety communication.
Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women.
Fertil Steril. Oestrogens and overactive bladder. Neurourol Urodyn. Estrogen levels influence betaadrenoceptor-mediated relaxation of the female rat detrusor muscle. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women.
Effects of estrogen with and without progestin on urinary incontinence. Oestrogen therapy for urinary incontinence in post-menopausal women. Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review. Female Pelvic Med Reconstr Surg. The impact of multimorbidity on sexual function in middle-aged and older women: beyond the single disease perspective.
J Sex Med. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health across the Nation. Are changes in sexual functioning during midlife due to aging or menopause? Sexual function in the late postmenopause: a decade of follow-up in a population-based cohort of Australian women. Oophorectomy: the debate between ovarian conservation and elective oophorectomy.
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Nappi RE, Domoney C.
Pharmacogenomics and sexuality: a vision. Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother. Quality of life and the role of menopausal hormone therapy. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
Gynecol Endocrinol. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial.
The benefits and harms of systemic dehydroepiandrosterone DHEA in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. Testosterone for low libido in postmenopausal women not taking estrogen. Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women.
Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
Cardiovascular disease outcomes during 6. Estrogen plus progestin and the risk of coronary heart disease. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis.
J Gen Intern Med. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Vascular effects of early versus late postmenopausal treatment with estradiol. Estrogen therapy and coronary-artery calcification.
Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. J Stroke. Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. Ethnic distribution of factor V Leiden in men and women. Implications for venous thromboembolism screening. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Women's Health Initiative Investigators.
Estrogen plus progestin and risk of venous thrombosis. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U. Preventive Services Task Force. A case of deep vein thromboembolism and Pulmonary embolism in postmenopausal hormone replacement therapy. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Hormone replacement therapy and breast cancer: a qualitative review.
Int J Cancer. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer. Marsden J British Menopause Society. The risks and benefits of HRT before and after a breast cancer diagnosis.
Post Reprod Health. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.
Lancet Oncol. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. Unopposed estrogen therapy and the risk of invasive breast cancer. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
Breast Cancer Res Treat. J Clin Oncol. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Fam Cancer. Holmberg L, Anderson H. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Korean Breast Cancer Society.
Seoul: Korean Breast Cancer Society; United States cancer statistics: data visualizations. National Cancer Institute. Cancer stat facts: female breast cancer. National Cancer Information Center. Goyang: National Cancer Information Center; Available from: www. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. Safety of hormone replacement therapy in gynaecological cancer survivors.
J Obstet Gynaecol. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study.
Am J Epidemiol. Estrogen plus progestin and colorectal cancer in postmenopausal women. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol. Oestrogen plus progestin and lung cancer in postmenopausal women Women's Health Initiative trial : a post-hoc analysis of a randomised controlled trial. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry.
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study.
PLoS Med. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. Hormone therapy and risk of Alzheimer disease: a critical time. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.
Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies.
Gonadal hormones and cognitive aging: a midlife perspective. Womens Health Lond ; 7 — Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Sherwin BB. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. Seoul National University College of Medicine.
The epidemiological survey of mental disorders in Korea Seoul: Korean Ministry of Health and Welfare; A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women.
Am J Psychiatry. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. Estrogen improves psychological function in asymptomatic postmenopausal women.
Estrogen replacement in perimenopause-related depression: a preliminary report. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.
Efficacy of estradiol in perimenopausal depression: so much promise and so few answers. Depress Anxiety. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. Yalamanchili V, Gallagher JC.
Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. North American Menopause Society.
The hormone therapy position statement of: the North American Menopause Society. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Meta-analyses of therapies for postmenopausal osteoporosis. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment NORA study.
Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int. Bone response to hormone therapy according to basal bone mineral density and previous response to hormone therapy. Jang HC. How to diagnose sarcopenia in Korean older adults? Ann Geriatr Med Res. Investigation of sarcopenia and its association with cardiometabolic risk factors in elderly subjects. J Korean Geriatr Soc.
Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes Lond ; 33 — J Bone Metab. Park HM. Current status of sarcopenia in Korea: a focus on Korean geripausal women. Prevalence of sarcopenia adjusted body mass index in the Korean woman based on the Korean National Health and Nutritional Examination Surveys. Effects of physical activity and menopausal hormone replacement therapy on postural stability in postmenopausal women--a cross-sectional study.
Chun SW. The Korean Society of Sarcopenia, editors. Paju: Koonja; Female hormones; pp. Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative.
Am J Clin Nutr. Soy isoflavones and exercise to improve physical capacity in postmenopausal women. Effect of estrogen therapy on gallbladder disease. Postmenopausal hormone replacement therapy. Panay N, Kalu E. Management of premature ovarian failure. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study.
Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices: a 6-month, prospective, randomized, placebo-controlled, double-blind study. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. This content does not have an English version. This content does not have an Arabic version.
See more conditions. Hormone therapy: Is it right for you? Products and services. By Mayo Clinic Staff. Thank you for subscribing Our Housecall e-newsletter will keep you up-to-date on the latest health information.
Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. Show references AskMayoExpert. Menopausal hormone therapy adult. Mayo Clinic; HRT has been shown to modify the sulting in more biologically active estrogen in circulation. Breast cancer risk is higher among women who take BMI and weight gain separately among current HRT HRT particularly the combination of estrogen plus progester- users and nonusers.
This study includes 1, incident one than in women who do not take hormones in both obser- breast cancer cases occurring among 62, vational studies 4, 5 and a clinical trial 6. Age-adjusted incidence rates were weight and postmenopausal breast cancer risk. A statistical calculated, and Cox proportional hazards models were interaction between HRT use and BMI for postmenopausal used to examine the association of BMI and adult weight breast cancer risk was first demonstrated in a cohort study by gain since age 18 years with breast cancer risk stratified Huang et al.
Most subsequent studies have supported these by HRT use. Weight gain of 21—30 pounds was BMI 11—13 despite some attenuation of the positive associ- associated with a rate ratio of 1. Our analysis examines the risk at age 18 were independent predictors of risk. Among of incident breast cancer in relation to reported BMI at age 18 current HRT users, no association was seen between years, BMI in up to 7 years before breast cancer diag- breast cancer and either BMI or weight gain.
Adult nosis , and weight gain between these two time periods among weight gain is strongly associated with postmenopausal 62, postmenopausal women. These data illustrate the importance of examining breast cancer risk factors separately by HRT use; the effects of Materials and Methods other risk factors may be attenuated or obscured among Study Cohort.
Women in this analysis were drawn from the women taking HRT. The Nutrition Cohort is a subgroup of cancer and has been the subject of extensive study 1.
Nutrition Cohort participants were recruited from origi- breast cancer. This phenomenon likely results from an in- nal members of the CPS-II cohort who resided in 21 states and were ages 50 —74 years in This article must therefore be hereby marked advertisement in Follow-up questionnaires were sent to all living cohort mem- accordance with 18 U.
Section solely to indicate this fact. Requests for reprints: Dr. Phone: ; Fax: September to August to update exposure informa- ; E-mail: heather. The response Downloaded from cebp.
Use of both 4, We also excluded participants who reported prevalent estrogen only and combination estrogen and progesterone for- breast or other cancer at baseline, except nonmelanoma skin mulations was determined. We excluded participants with extreme values for weight gain were similar in the two groups. We calculated age-adjusted breast cancer above the All models were stratified on single year of age at 6, After all exclusions, the final analytic cohort consisted enrollment.
We documented incident cases of unknown , family history of breast cancer in mother or sister breast cancer diagnosed between enrollment in and Au- yes or no , personal history of breast cysts yes or no , screen- gust 31, Eighty baseline; Ref.
An additional 59 women iden- ers described above and by attained age, interaction terms tified using the National Death Index 16 for whom the death between total adult weight gain age 18 years to , BMI in certificate listed breast cancer as a primary or contributory , and BMI at age 18 years as categorical variables, and cause of death International Classification of Diseases, Ninth each of the other risk factors were included in multivariate Revision, codes We evaluated the significance of potential interactions Forty-four of the 59 interval deaths were subsequently verified.
Results Anthropometric Measures. On the baseline questionnaire in The relationship between breast cancer risk and either BMI at , participants were asked to report their height, current baseline or weight gain since age 18 years was qualitatively weight, and weight at age 18 years.
BMI was calculated as different in women who reported current HRT use from those weight in kilograms divided by the square of height in meters who reported no use or past use at baseline. Total adult weight change from age 18 years to cases. HRT Use. Compared with or prevention of disease such as bone loss? Table 3. How- 0. Including adult ever, when total adult weight gain was added to the multivariate weight gain in the multivariate model did not change the RR model, the increased risk associated with BMI was attenuated estimates.
Among women who were using HRT at baseline, in- enopausal breast cancer risk was influenced by the BMI at age creasing BMI was not associated with increased risk of breast 18 years. In stratified analysis, total adult weight gain among cancer. This trend reached statistical significance regardless of BMI at age 18 years data not shown.
We also ob- more strongly associated with breast cancer risk Table 3 than served no evidence of effect modification by attained age. Fur- thermore, the association between adult weight gain and breast Discussion cancer risk remained statistically significant in analyses con- In this large prospective study, total adult weight gain was trolling for current BMI among non-HRT users Table 3.
Among women using association between breast cancer and body size by HRT use. HRT, we found no increased risk associated with adult weight In these two studies, risk of breast cancer was clearly elevated gain. In contrast, two other recent studies, one large population- Most 1, 4, 7—10 but not all 11—13 previous studies have based case-control study 12 and one cohort study 11 , did not found that HRT use modifies the effect of body weight on risk observe statistically significant interaction between weight or of breast cancer.
Downloaded from cebp.
0コメント